-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 2, Renfu Pharmaceutical announced that it planned to transfer 680,087,537 Tianfeng Securities shares to Hubei Hongtai Group Co.
, Ltd.
by way of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
, Ltd.
by way of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
01Enterprise announcement
The content of the announcement shows:
In order to focus on the main business and optimize the company's business structure and asset-liability structure, the company and Hongtai Group signed the "Conditional Share Transfer Agreement Regarding the 7.
85% Shares of Tianfeng Securities Co.
, Ltd.
" on March 31, 2022.
680,087,537 Tianfeng Securities shares were transferred to Hubei Hongtai Group Co.
, Ltd.
by means of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
85% Shares of Tianfeng Securities Co.
, Ltd.
" on March 31, 2022.
680,087,537 Tianfeng Securities shares were transferred to Hubei Hongtai Group Co.
, Ltd.
by means of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
Within 5 working days after the signing of this agreement, Party B shall pay Party A 20,000,000 yuan as the transaction earnest money
.
When this agreement takes effect, the earnest money will be automatically converted into the first-phase share transfer price
.
.
When this agreement takes effect, the earnest money will be automatically converted into the first-phase share transfer price
.
Party B shall pay Party A RMB 1,300,000,000 as the second-phase share transfer price within 2 working days after all the conditions stipulated in this agreement come into effect
.
.
The second-phase share transfer price shall be used to repay Party A's stock-pledged loan held by Tianfeng Securities
.
Party A shall guarantee that China Merchants Bank will handle the release of Party A's stock pledge within 1 working day from the date of receipt of the second installment of the share transfer price paid by Party
B.
Party A shall go through the transfer procedures of the underlying shares within 2 working days after the shares are released from the pledge
.
.
Party A shall guarantee that China Merchants Bank will handle the release of Party A's stock pledge within 1 working day from the date of receipt of the second installment of the share transfer price paid by Party
B.
Party A shall go through the transfer procedures of the underlying shares within 2 working days after the shares are released from the pledge
.
Party B shall pay the remaining share transfer price of RMB 803,913,378.
05 to Party A's bank account designated by Party A within 5 working days after the completion of the transfer of the underlying shares
.
05 to Party A's bank account designated by Party A within 5 working days after the completion of the transfer of the underlying shares
.
02About the acquisition of the company
Hongtai Group is a first-class state-owned commercial platform enterprise
supervised and managed by the State-owned Assets Supervision and Administration Commission of the Hubei Provincial Government .
supervised and managed by the State-owned Assets Supervision and Administration Commission of the Hubei Provincial Government .
As of December 31, 2021, Hongtai Group has total assets of RMB 61,903,093,900, net assets of RMB 20,997,712,700, operating income of RMB 14,063,467,300 in 2021, and net profit of RMB 532,009,100
.
.
03Review of sales information of more than pharmaceutical companies
Under the influence of the country's continuous promotion of medical reform policies, the competition among pharmaceutical companies is also intensifying.
In order to compete for the market and focus on the company's business, many pharmaceutical companies have also chosen to sell assets one after another
.
In order to compete for the market and focus on the company's business, many pharmaceutical companies have also chosen to sell assets one after another
.
On March 30, 2022, Ruizhi Pharmaceutical Technology Co.
, Ltd.
issued an announcement on the sale of 100% equity of Quantum Hi-Tech (Guangdong) Biological Co.
, Ltd.
The transaction price is expected to be US$237 million, equivalent to RMB 1.
5 billion
.
, Ltd.
issued an announcement on the sale of 100% equity of Quantum Hi-Tech (Guangdong) Biological Co.
, Ltd.
The transaction price is expected to be US$237 million, equivalent to RMB 1.
5 billion
.
On March 29, Xinrui Medicine announced that Major Bright Holdings Limited, a wholly-owned subsidiary of the company, plans to sell a 25% stake in the target company SECCO International Medical Group Co.
, Ltd.
for RMB 44 million
.
For the sale of this asset, the company said it will focus on the promising Chinese patent medicine market and sales
.
, Ltd.
for RMB 44 million
.
For the sale of this asset, the company said it will focus on the promising Chinese patent medicine market and sales
.
On March 18, Tonghua Dongbao announced that it planned to transfer 5.
04% shares of Tebao Bio to Guangzhou Houbao Investment Partnership (Limited Partnership) by agreement transfer.
The transfer price was 20.
16 yuan per share, and the total transfer price was 413 million yuan.
.
This move, the company said, is conducive to the return of funds and provides financial support for Tonghua Dongbao to deploy innovative drugs
.
04% shares of Tebao Bio to Guangzhou Houbao Investment Partnership (Limited Partnership) by agreement transfer.
The transfer price was 20.
16 yuan per share, and the total transfer price was 413 million yuan.
.
This move, the company said, is conducive to the return of funds and provides financial support for Tonghua Dongbao to deploy innovative drugs
.
On January 29, Guangdong VTR Biotech announced that it planned to sell its 74.
8057% stake in Hunan Xinhexin Biopharmaceutical Co.
, Ltd.
, 100% stake in Hunan Keyixin Biopharmaceutical Co.
, Ltd.
and Henan Lihua Pharmaceutical Co.
, Ltd.
100% equity of the company
.
After the completion of this transaction, it means that the company will divest all assets related to the biopharmaceutical business
.
8057% stake in Hunan Xinhexin Biopharmaceutical Co.
, Ltd.
, 100% stake in Hunan Keyixin Biopharmaceutical Co.
, Ltd.
and Henan Lihua Pharmaceutical Co.
, Ltd.
100% equity of the company
.
After the completion of this transaction, it means that the company will divest all assets related to the biopharmaceutical business
.
On January 26, Shapuaisi Pharmaceutical announced that its subsidiary, Qiangsheng Pharmaceutical (Jilin), was sold to Yueshi Pharmaceutical at a delisting price of 82 million yuan
.
It is reported that the subsidiary was acquired by the former actual controller of Shapuaisi through a non-public offering in 2015.
The main business is the production of Chinese patent medicines.
liquid,
etc.
For this sale, the company said it will help reduce listing losses in the future and have a positive impact on its future financial status
.
.
It is reported that the subsidiary was acquired by the former actual controller of Shapuaisi through a non-public offering in 2015.
The main business is the production of Chinese patent medicines.
liquid,
etc.
For this sale, the company said it will help reduce listing losses in the future and have a positive impact on its future financial status
.
On January 18, Zhejiang Xianju Pharmaceutical issued an announcement on the proposed transfer of 61.
2% equity of its holding subsidiary Haisheng Pharmaceutical
.
After this transfer, the company will no longer hold the equity of Haisheng Pharmaceutical
.
It is reported that Haisheng Pharmaceutical's main business is the production and sales of raw materials (vitamin D3) and other products, but in recent years, the company has shown a downward trend
.
2% equity of its holding subsidiary Haisheng Pharmaceutical
.
After this transfer, the company will no longer hold the equity of Haisheng Pharmaceutical
.
It is reported that Haisheng Pharmaceutical's main business is the production and sales of raw materials (vitamin D3) and other products, but in recent years, the company has shown a downward trend
.
On April 2, Renfu Pharmaceutical announced that it planned to transfer 680,087,537 Tianfeng Securities shares to Hubei Hongtai Group Co.
, Ltd.
by way of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
, Ltd.
by way of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
01Enterprise announcement
The content of the announcement shows:
In order to focus on the main business and optimize the company's business structure and asset-liability structure, the company and Hongtai Group signed the "Conditional Share Transfer Agreement Regarding the 7.
85% Shares of Tianfeng Securities Co.
, Ltd.
" on March 31, 2022.
680,087,537 Tianfeng Securities shares were transferred to Hubei Hongtai Group Co.
, Ltd.
by means of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
85% Shares of Tianfeng Securities Co.
, Ltd.
" on March 31, 2022.
680,087,537 Tianfeng Securities shares were transferred to Hubei Hongtai Group Co.
, Ltd.
by means of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
Within 5 working days after the signing of this agreement, Party B shall pay Party A 20,000,000 yuan as the transaction earnest money
.
When this agreement takes effect, the earnest money will be automatically converted into the first-phase share transfer price
.
.
When this agreement takes effect, the earnest money will be automatically converted into the first-phase share transfer price
.
Party B shall pay Party A RMB 1,300,000,000 as the second-phase share transfer price within 2 working days after all the conditions stipulated in this agreement come into effect
.
.
The second-phase share transfer price shall be used to repay Party A's stock-pledged loan held by Tianfeng Securities
.
Party A shall guarantee that China Merchants Bank will handle the release of Party A's stock pledge within 1 working day from the date of receipt of the second installment of the share transfer price paid by Party
B.
Party A shall go through the transfer procedures of the underlying shares within 2 working days after the shares are released from the pledge
.
.
Party A shall guarantee that China Merchants Bank will handle the release of Party A's stock pledge within 1 working day from the date of receipt of the second installment of the share transfer price paid by Party
B.
Party A shall go through the transfer procedures of the underlying shares within 2 working days after the shares are released from the pledge
.
Party B shall pay the remaining share transfer price of RMB 803,913,378.
05 to Party A's bank account designated by Party A within 5 working days after the completion of the transfer of the underlying shares
.
05 to Party A's bank account designated by Party A within 5 working days after the completion of the transfer of the underlying shares
.
02About the acquisition of the company
Hongtai Group is a first-class state-owned commercial platform enterprise
supervised and managed by the State-owned Assets Supervision and Administration Commission of the Hubei Provincial Government .
supervised and managed by the State-owned Assets Supervision and Administration Commission of the Hubei Provincial Government .
As of December 31, 2021, Hongtai Group has total assets of RMB 61,903,093,900, net assets of RMB 20,997,712,700, operating income of RMB 14,063,467,300 in 2021, and net profit of RMB 532,009,100
.
.
03Review of sales information of more than pharmaceutical companies
Under the influence of the country's continuous promotion of medical reform policies, the competition among pharmaceutical companies is also intensifying.
In order to compete for the market and focus on the company's business, many pharmaceutical companies have also chosen to sell assets one after another
.
In order to compete for the market and focus on the company's business, many pharmaceutical companies have also chosen to sell assets one after another
.
On March 30, 2022, Ruizhi Pharmaceutical Technology Co.
, Ltd.
issued an announcement on the sale of 100% equity of Quantum Hi-Tech (Guangdong) Biological Co.
, Ltd.
The transaction price is expected to be US$237 million, equivalent to RMB 1.
5 billion
.
, Ltd.
issued an announcement on the sale of 100% equity of Quantum Hi-Tech (Guangdong) Biological Co.
, Ltd.
The transaction price is expected to be US$237 million, equivalent to RMB 1.
5 billion
.
On March 29, Xinrui Medicine announced that Major Bright Holdings Limited, a wholly-owned subsidiary of the company, plans to sell a 25% stake in the target company SECCO International Medical Group Co.
, Ltd.
for RMB 44 million
.
For the sale of this asset, the company said it will focus on the promising Chinese patent medicine market and sales
.
, Ltd.
for RMB 44 million
.
For the sale of this asset, the company said it will focus on the promising Chinese patent medicine market and sales
.
On March 18, Tonghua Dongbao announced that it planned to transfer 5.
04% shares of Tebao Bio to Guangzhou Houbao Investment Partnership (Limited Partnership) by agreement transfer.
The transfer price was 20.
16 yuan per share, and the total transfer price was 413 million yuan.
.
This move, the company said, is conducive to the return of funds and provides financial support for Tonghua Dongbao to deploy innovative drugs
.
04% shares of Tebao Bio to Guangzhou Houbao Investment Partnership (Limited Partnership) by agreement transfer.
The transfer price was 20.
16 yuan per share, and the total transfer price was 413 million yuan.
.
This move, the company said, is conducive to the return of funds and provides financial support for Tonghua Dongbao to deploy innovative drugs
.
On January 29, Guangdong VTR Biotech announced that it planned to sell its 74.
8057% stake in Hunan Xinhexin Biopharmaceutical Co.
, Ltd.
, 100% stake in Hunan Keyixin Biopharmaceutical Co.
, Ltd.
and Henan Lihua Pharmaceutical Co.
, Ltd.
100% equity of the company
.
After the completion of this transaction, it means that the company will divest all assets related to the biopharmaceutical business
.
8057% stake in Hunan Xinhexin Biopharmaceutical Co.
, Ltd.
, 100% stake in Hunan Keyixin Biopharmaceutical Co.
, Ltd.
and Henan Lihua Pharmaceutical Co.
, Ltd.
100% equity of the company
.
After the completion of this transaction, it means that the company will divest all assets related to the biopharmaceutical business
.
On January 26, Shapuaisi Pharmaceutical announced that its subsidiary, Qiangsheng Pharmaceutical (Jilin), was sold to Yueshi Pharmaceutical at a delisting price of 82 million yuan
.
It is reported that the subsidiary was acquired by the former actual controller of Shapuaisi through a non-public offering in 2015.
The main business is the production of Chinese patent medicines.
liquid,
etc.
For this sale, the company said it will help reduce listing losses in the future and have a positive impact on its future financial status
.
.
It is reported that the subsidiary was acquired by the former actual controller of Shapuaisi through a non-public offering in 2015.
The main business is the production of Chinese patent medicines.
liquid,
etc.
For this sale, the company said it will help reduce listing losses in the future and have a positive impact on its future financial status
.
On January 18, Zhejiang Xianju Pharmaceutical issued an announcement on the proposed transfer of 61.
2% equity of its holding subsidiary Haisheng Pharmaceutical
.
After this transfer, the company will no longer hold the equity of Haisheng Pharmaceutical
.
It is reported that Haisheng Pharmaceutical's main business is the production and sales of raw materials (vitamin D3) and other products, but in recent years, the company has shown a downward trend
.
2% equity of its holding subsidiary Haisheng Pharmaceutical
.
After this transfer, the company will no longer hold the equity of Haisheng Pharmaceutical
.
It is reported that Haisheng Pharmaceutical's main business is the production and sales of raw materials (vitamin D3) and other products, but in recent years, the company has shown a downward trend
.
On April 2, Renfu Pharmaceutical announced that it planned to transfer 680,087,537 Tianfeng Securities shares to Hubei Hongtai Group Co.
, Ltd.
by way of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
, Ltd.
by way of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
01Enterprise announcement
01Enterprise announcement The content of the announcement shows:
The content of the announcement shows: In order to focus on the main business and optimize the company's business structure and asset-liability structure, the company and Hongtai Group signed the "Conditional Share Transfer Agreement Regarding the 7.
85% Shares of Tianfeng Securities Co.
, Ltd.
" on March 31, 2022.
680,087,537 Tianfeng Securities shares were transferred to Hubei Hongtai Group Co.
, Ltd.
by means of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
85% Shares of Tianfeng Securities Co.
, Ltd.
" on March 31, 2022.
680,087,537 Tianfeng Securities shares were transferred to Hubei Hongtai Group Co.
, Ltd.
by means of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
Within 5 working days after the signing of this agreement, Party B shall pay Party A 20,000,000 yuan as the transaction earnest money
.
When this agreement takes effect, the earnest money will be automatically converted into the first-phase share transfer price
.
.
When this agreement takes effect, the earnest money will be automatically converted into the first-phase share transfer price
.
Party B shall pay Party A RMB 1,300,000,000 as the second-phase share transfer price within 2 working days after all the conditions stipulated in this agreement come into effect
.
.
The second-phase share transfer price shall be used to repay Party A's stock-pledged loan held by Tianfeng Securities
.
Party A shall guarantee that China Merchants Bank will handle the release of Party A's stock pledge within 1 working day from the date of receipt of the second installment of the share transfer price paid by Party
B.
Party A shall go through the transfer procedures of the underlying shares within 2 working days after the shares are released from the pledge
.
Investment promotion _.
Party A shall guarantee that China Merchants Bank will handle the release of Party A's stock pledge within 1 working day from the date of receipt of the second installment of the share transfer price paid by Party
B.
Party A shall go through the transfer procedures of the underlying shares within 2 working days after the shares are released from the pledge
.
Party B shall pay the remaining share transfer price of RMB 803,913,378.
05 to Party A's bank account designated by Party A within 5 working days after the completion of the transfer of the underlying shares
.
05 to Party A's bank account designated by Party A within 5 working days after the completion of the transfer of the underlying shares
.
02About the acquisition of the company
02About the acquisition of the companyHongtai Group is a first-class state-owned commercial platform enterprise
supervised and managed by the State-owned Assets Supervision and Administration Commission of the Hubei Provincial Government .
enterprise enterprise enterprisesupervised and managed by the State-owned Assets Supervision and Administration Commission of the Hubei Provincial Government .
As of December 31, 2021, Hongtai Group has total assets of RMB 61,903,093,900, net assets of RMB 20,997,712,700, operating income of RMB 14,063,467,300 in 2021, and net profit of RMB 532,009,100
.
.
03Review of sales information of more than pharmaceutical companies
03Review of sales information of more than pharmaceutical companies Under the influence of the country's continuous promotion of medical reform policies, the competition among pharmaceutical companies is also intensifying.
In order to compete for the market and focus on the company's business, many pharmaceutical companies have also chosen to sell assets one after another
.
medicine medicine medicineIn order to compete for the market and focus on the company's business, many pharmaceutical companies have also chosen to sell assets one after another
.
On March 30, 2022, Ruizhi Pharmaceutical Technology Co.
, Ltd.
issued an announcement on the sale of 100% equity of Quantum Hi-Tech (Guangdong) Biological Co.
, Ltd.
The transaction price is expected to be US$237 million, equivalent to RMB 1.
5 billion
.
, Ltd.
issued an announcement on the sale of 100% equity of Quantum Hi-Tech (Guangdong) Biological Co.
, Ltd.
The transaction price is expected to be US$237 million, equivalent to RMB 1.
5 billion
.
On March 29, Xinrui Medicine announced that Major Bright Holdings Limited, a wholly-owned subsidiary of the company, plans to sell a 25% stake in the target company SECCO International Medical Group Co.
, Ltd.
for RMB 44 million
.
For the sale of this asset, the company said it will focus on the promising Chinese patent medicine market and sales
.
, Ltd.
for RMB 44 million
.
For the sale of this asset, the company said it will focus on the promising Chinese patent medicine market and sales
.
On March 18, Tonghua Dongbao announced that it planned to transfer 5.
04% shares of Tebao Bio to Guangzhou Houbao Investment Partnership (Limited Partnership) by agreement transfer.
The transfer price was 20.
16 yuan per share, and the total transfer price was 413 million yuan.
.
This move, the company said, is conducive to the return of funds and provides financial support for Tonghua Dongbao to deploy innovative drugs
.
04% shares of Tebao Bio to Guangzhou Houbao Investment Partnership (Limited Partnership) by agreement transfer.
The transfer price was 20.
16 yuan per share, and the total transfer price was 413 million yuan.
.
This move, the company said, is conducive to the return of funds and provides financial support for Tonghua Dongbao to deploy innovative drugs
.
On January 29, Guangdong VTR Biotech announced that it planned to sell its 74.
8057% stake in Hunan Xinhexin Biopharmaceutical Co.
, Ltd.
, 100% stake in Hunan Keyixin Biopharmaceutical Co.
, Ltd.
and Henan Lihua Pharmaceutical Co.
, Ltd.
100% equity of the company
.
After the completion of this transaction, it means that the company will divest all assets related to the biopharmaceutical business
.
8057% stake in Hunan Xinhexin Biopharmaceutical Co.
, Ltd.
, 100% stake in Hunan Keyixin Biopharmaceutical Co.
, Ltd.
and Henan Lihua Pharmaceutical Co.
, Ltd.
100% equity of the company
.
After the completion of this transaction, it means that the company will divest all assets related to the biopharmaceutical business
.
On January 26, Shapuaisi Pharmaceutical announced that its subsidiary, Qiangsheng Pharmaceutical (Jilin), was sold to Yueshi Pharmaceutical at a delisting price of 82 million yuan
.
It is reported that the subsidiary was acquired by the former actual controller of Shapuaisi through a non-public offering in 2015.
The main business is the production of Chinese patent medicines.
liquid,
etc.
For this sale, the company said it will help reduce listing losses in the future and have a positive impact on its future financial status
.
.
It is reported that the subsidiary was acquired by the former actual controller of Shapuaisi through a non-public offering in 2015.
The main business is the production of Chinese patent medicines.
liquid,
etc.
For this sale, the company said it will help reduce listing losses in the future and have a positive impact on its future financial status
.
On January 18, Zhejiang Xianju Pharmaceutical issued an announcement on the proposed transfer of 61.
2% equity of its holding subsidiary Haisheng Pharmaceutical
.
After this transfer, the company will no longer hold the equity of Haisheng Pharmaceutical
.
It is reported that Haisheng Pharmaceutical's main business is the production and sales of raw materials (vitamin D3) and other products, but in recent years, the company has shown a downward trend
.
2% equity of its holding subsidiary Haisheng Pharmaceutical
.
After this transfer, the company will no longer hold the equity of Haisheng Pharmaceutical
.
It is reported that Haisheng Pharmaceutical's main business is the production and sales of raw materials (vitamin D3) and other products, but in recent years, the company has shown a downward trend
.
